Roundtables
Advertisement
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
The panel concludes with the challenges of implementing cutting-edge research into colorectal cancer care and practice.
The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.
The panel expands on the incorporation of ctDNA in the CRC adjuvant setting, highlighting its prognostic value.
The panel details strategies for managing oligometastatic CRC, emphasizing the importance of a multidisciplinary approach.
The panel swaps opinions on advancements in EGFR and KRAS inhibitors, as well as the importance of NGS and liquid biopsy.
The panel focuses on the evolution of CRC treatment paradigms, including advances in chemo, biologic agents, and more.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.